2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of …

F Mach, C Baigent, AL Catapano… - European heart …, 2020 - academic.oup.com
version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …

Racial and ethnic disparities in peripheral artery disease

EL Hackler III, NM Hamburg… - Circulation research, 2021 - Am Heart Assoc
Peripheral artery disease is an obstructive, atherosclerotic disease of the lower extremities
causing significant morbidity and mortality. Black Americans are disproportionately affected …

[PDF][PDF] 2016 ESC/EAS guidelines for the management of dyslipidaemias

AL Catapano, I Graham, G De Backer… - Polish Heart …, 2016 - journals.viamedica.pl
5.1. Wpływ stylu życia na stężenie cholesterolu całkowitego i stężenie cholesterolu frakcji
lipoprotein o małej gęstości................................ 1259 5.2. Wpływ stylu życia na stężenie …

Underuse of prevention and lifestyle counseling in patients with peripheral artery disease

JS Berger, JA Ladapo - Journal of the American College of Cardiology, 2017 - jacc.org
Background: Little is known about patterns of medication use and lifestyle counseling in
patients with peripheral artery disease (PAD) in the United States. Objectives: The authors …

A review of the pathophysiology and potential biomarkers for peripheral artery disease

SM Krishna, JV Moxon, J Golledge - International journal of molecular …, 2015 - mdpi.com
Peripheral artery disease (PAD) is due to the blockage of the arteries supplying blood to the
lower limbs usually secondary to atherosclerosis. The most severe clinical manifestation of …

[PDF][PDF] 2016 ESC/EAS guidelines for the management of dyslipidaemias

MT Cooney, E Bruckert, A Cordero, A Corsini… - European heart …, 2016 - iris.unime.it
The content of these European Society of Cardiology (ESC) and European Atherosclerosis
Society Guidelines has been published for personal and educational use only. No …

[HTML][HTML] Ten year mortality in different peripheral arterial disease stages: a population based observational study on outcome

F Sartipy, B Sigvant, F Lundin, E Wahlberg - European Journal of Vascular …, 2018 - Elsevier
Objective The aim was to determine long-term mortality rates and the underlying cause of
death for subjects with different peripheral arterial disease (PAD) stages in a population …

Polyvascular disease and risk of major adverse cardiovascular events in peripheral artery disease: a secondary analysis of the EUCLID trial

JA Gutierrez, H Mulder, WS Jones… - JAMA network …, 2018 - jamanetwork.com
Importance The effect of polyvascular disease on cardiovascular outcomes in the
background of peripheral artery disease (PAD) is unclear. Objective To determine the risk of …

SIRT1 as a therapeutic target in diabetic complications

J Strycharz, Z Rygielska, E Swiderska… - Current medicinal …, 2018 - ingentaconnect.com
Background: Sirtuin1 is an epigenetic enzyme involved in histone and nonhistone protein
deacetylation. It acts primarily as a metabolic sensor, which responses to changing energy …

Enhancement of functionality and therapeutic efficacy of cell-based therapy using mesenchymal stem cells for cardiovascular disease

CW Yun, SH Lee - International journal of molecular sciences, 2019 - mdpi.com
Cardiovascular disease usually triggers coronary heart disease, stroke, and ischemic
diseases, thus promoting the development of functional failure. Mesenchymal stem cells …